With multiple ADCs now available for use in gynecologic cancers, treatment decision-making incorporates biomarker nuances and raises sequencing questions.
Refined ADC Development Helps Weigh Biomarker-Based Decisions and Treatment Sequencing in Gynecologic Cancers
